drugset / Trial / NCT00607399
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-01
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGX523 | Small molecule | — | Oral |
Indications
No indication recorded.